

PRESS RELEASE - FOR IMMEDIATE RELEASE

IntegraGen

Oncology - liver and colon cancer: award of OSEO funding for a biomarker panel development project.

Evry (France), April 27, 2011. The French molecular diagnostics and genomic services company IntegraGen today announced that OSEO (the French state innovation agency) had awarded a total of €1.6 million in financial support to a collaborative project with the French National Institute of Health and Medical Research (INSERM).

The financial support covers a 3-year period and will be supplied by OSEO as an interest-free loan that will be repayable from 2015 onwards if the project is successful.

The project (to be performed in collaboration with INSERM units U674 and U775) is notably based on promising research themes identified during the *Carte d'Identité des Tumeurs* ("Tumor ID Card") program funded by the French National League Against Cancer. The collaboration aims at developing tools (biomarker panels) for personalized medicine and the management of liver and colon cancer patients.

IntegraGen's goal is to (i) prospective validate (under clinical conditions and with several hundred patients) research results generated by the two INSERM units and (ii) develop and implement a panel of diagnostic tests by 2013.

IntegraGen's President and CEO Bernard Courtieu commented: *"We are delighted to have obtained this financial support, which constitutes a scientific and economic validation of the avenues identified by the INSERM and IntegraGen researchers. These resources will enable us to leverage the development of diagnostic tests and schedule a market launch by 2013."*

Professor Pierre Laurent-Puig (faculty member at the Descartes University of Paris and Director of INSERM unit UMR-S775, whose work in pharmacogenomics revealed the role of the KRAS mutation in the response to anti-EGFR therapies in colon cancer) added: *"We are taking a major step forward in the development of personalized medicine tools for digestive oncology and are particularly delighted to form part of an academic and industrial consortium with acknowledged expertise."*

Professor Jessica Zucman-Rossi (also a faculty member at the Descartes University of Paris and Director of INSERM unit UMR-S674) added: *"This collaboration will catalyze the development of one of the first tools for truly personalized medicine for these types of liver tumor by enabling a significant improvement in tumor staging and the development of more efficacious treatments guided by molecular typing"*.

ABOUT INTEGRAGEN

IntegraGen (founded in 2000 and based in Evry, France) is a biotech company developing molecular diagnostic products and services that provide clinicians with new tools to personalize diagnosis, treatment and therapy. IntegraGen and its wholly owned U.S. subsidiary IntegraGen, Inc., are focused on the prevention and proactive management of complex, debilitating diseases and dedicated to addressing the needs of patients, clinicians and advocacy groups. IntegraGen's Genetic Services business division also provides state-of-the-art genotyping services to the research community. With discovery activities and intellectual property focused on autism and oncology, IntegraGen's core strategy is to deliver a portfolio of high-value molecular diagnostic products and services that drive personalized healthcare solutions for complex diseases.

IntegraGen is listed on the Alternext market at NYSE Euronext Paris (ISIN code: FR0010908723; ticker Code: ALINT). For more information, visit www.integragen.com.

ABOUT THE INSERM

The INSERM is France's only public-sector organization entirely dedicated to biological & medical research and public health. Its researchers study all types of disease, from the most common to the very rarest conditions. The INSERM coordinates this research nationally via 10 thematic institutes: cancer; circulation, metabolism and nutrition; genetics, genomics and bioinformatics; the molecular and structural basis of life; cell biology, development and evolution; immunology, hematology, pneumology; infectious diseases. The INSERM is a member of the AVIESAN National Alliance for Life Science and Healthcare, founded in April 2009 with the CNRS, CEA, INRA, INRIA, IRD, the Pasteur Institute, the Council of University Presidents and the Council of University Medical Center Chief Executives. This alliance forms part of the French government's reform of the research system and seeks to better coordinate the various stakeholder and reinforce France's research in this sector through concerted planning. For more information, visit www.inserm.fr and www.aviesan.fr.

ABOUT OSEO

Oseo is a public-sector institution that provides entrepreneurs with the resources they need for innovation projects, investment programmes and international business development activities. It offers guidance and financial solutions for all the decisive phases in the corporate life cycle. Oseo collaborates closely with a network of European, national and regional partners to help initiate and commercialize high-potential, high-risk products and services.

For more information, contact delphine.peyrat-stricker@oseo.fr/vanessa.godet@oseo.fr

CONTACTS

INTEGRAGEN

Bernard Courtieu
President and CEO
contact@integragen.com
Tel: +33 (0)160 910 900

Patrick Court
CFO
contact@integragen.com
Tel: +33 (0)160 910 909

LT VALUE - INVESTOR RELATIONS AND CORPORATE COMMUNICATION

Investor relations: Nancy Levain / Maryline Jarnoux-Sorin
nancy.levain@ltvalue.com / maryline.jarnoux-sorin@ltvalue.com
Tel: +33 (0)144 503 930 - +33 (0)672 289 144

Press: Antoinette Darpy
antoinette.darpy@ltvalue.com
Tel: +33 (0)672 950 792